Home > Insider Trading > Filing (0001209191-21-041058)

Filing Details

Accession Number:: 0001209191-21-041058
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-16 18:20:07
Reporting Period:: 2021-06-15

Accepted Time:: 2021-06-16 18:20:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817713	Janux Therapeutics Inc.	JANX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1357522	A. Peter Thompson	C/O Janux Therapeutics, Inc. 11099 N. Torrey Pines Road, Suite 290 La Jolla CA 92037		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-15	1,348,421	$0.00	1,348,421	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2021-06-15	823,742	$0.00	2,172,163	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2021-06-15	588,203	$17.00	2,760,366	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2021-06-15	164,748	$0.00	164,748	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2021-06-15	117,650	$17.00	282,398	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2021-06-15	1,052,632	$0.00	1,348,421	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-06-15	643,046	$0.00	823,742	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-06-15	128,609	$0.00	164,748	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
The securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the generalpartner of OPI VIII and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII andAdvisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed tohave beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of CarlL. Gordon, Sven H. Borho, and Jonathan T. Silverstein. The Reporting Person is an employee of Advisors.
Each of Advisors, GP VIII, OrbiMed Genesis GP LLC ("Genesis GP"), and the Reporting Person disclaims beneficial ownership of the securitiesreported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent ofits or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner ofsuch securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
The shares were purchased in the Issuer's initial public offering.
The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Fund"). Genesis GP is the general partner of Genesis Fundand Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and Advisors may be deemed to have votingand investment power with respect to the shares held by Genesis Fund and as a result may be deemed to have beneficial ownership of suchshares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, andJonathan T. Silverstein. The Reporting Person is an employee of Advisors.